Completed PHASE3 INTERVENTIONAL 3-arm NCT00973609

Optimal Maintenance Therapy With Bevacizumab After Induction in Metastatic Colorectal Cancer (CRC)

Randomized Three Arm Phase III Trial on Induction Treatment With a Fluoropyrimidine-, Oxaliplatin- and Bevacizumab-based Chemotherapy for 24 Weeks Followed by Maintenance Treatment With a Fluoropyrimidine and Bevacizumab vs. Bevacizumab Alone vs. no Maintenance Treatment and Reinduction in Case of Progression for First-line Treatment of Patients With Metastatic Colorectal Cancer

Sponsor: AIO-Studien-gGmbH

Conditions Colorectal Neoplasms

Interventions 5-Fluorouracil, Folic acid, Capecitabine; Bevacizumab

Updated 5 times since 2017 Last updated: Aug 31, 2015 Started: Aug 31, 2009 Primary completion: Dec 31, 2014 Completion: Aug 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE3 clinical study on Colorectal Neoplasms, this trial is completed. The trial is conducted by AIO-Studien-gGmbH and has accumulated 5 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Jun 2018 — Jan 2021 [monthly]

Completed PHASE3
Jan 2017 — Jun 2018 [monthly]

Completed PHASE3

First recorded

Aug 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

AIO-Studien-gGmbH
Roche Pharma AG

Data source: AIO-Studien-gGmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Berlin, Germany